| UNITED STATES | |
| SECURITIES AND EXCHANGE COMMISSION | |
| Washington, D.C. 20549 | |
| Notice of Effectiveness | |
| Effectiveness Date: | August 22, 2022 |
| Accession Number: | 0001140361-22-029967 | ||||||
| Submission Type: | POS AM | ||||||
| |||||||
Turning Point Therapeutics is now a
Bristol Myers Squibb company
Select OK for information about Turning Point Therapeutics.
Select BMS to learn more about Bristol Myers Squibb